First New Ovarian Cancer Treatment in 20 Years

NHS just approved a groundbreaking new treatment for ovarian cancer — the first in two decades — offering women whose cancer resisted chemo a real chance at longer survival. Called mirvetuximab soravtansine, this “biological missile” drug zeroes in on cancer cells with pinpoint accuracy, slashing side effects while extending life by nearly four months on average. Tested across eight NHS hospitals, it’s now poised to help up to 400 patients annually in England — a major leap forward in precision medicine that’s giving hundreds of women renewed hope and precious time with loved ones. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/a59befa4becaa017